Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Presbyopia Clinical Trial

Official title:

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 (Aceclidine/Tropicamide) Ophthalmic Topical Formulation in the Treatment of Early to Moderate Presbyopia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02554396
• Other study ID #: PRX100.FDAII
• Status: Completed
• Phase: Phase 2
• First received: September 16, 2015
• Last updated: October 19, 2017
• Start date: September 2015
• Est. completion date: November 2015

Study information

• Verified date: October 2017
• Source: Presbyopia Therapies, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a one-day, randomized, double-masked, single-center evaluation of the efficacy and safety of PRX-100 ophthalmic solution compared to placebo in 20 subjects (randomized 4:1, PRX-100:placebo) to evaluate the safety of PRX-100 and the magnitude and duration of effects on improving near-vision acuity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 2015
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 59 Years

Eligibility

Inclusion Criteria:

1. be 45-59 years of age of either sex and any race or ethnicity;

2. be able and willing to provide written informed consent and sign HIPAA form prior to any study procedure being performed;

3. be able and willing to follow all instructions and attend all study visits;

4. have a negative urine pregnancy test at Visit 1, if female of childbearing potential (those who have experienced menarche and who are not surgically sterilized [bilateral tubal ligation, hysterectomy or bilateral oophorectomy] or post-menopausal [12 months after last menses]) and must use adequate birth control throughout the study period. Adequate birth control is defined as hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control;

5. be an early to moderate presbyope

6. be able and willing to avoid all disallowed medication(s) for the appropriate washout period and during the study without significant risk to the subject (see exclusion 15).

Exclusion Criteria:

1. have known contraindications or sensitivity to the use of any of the study medications(s) or their components;

2. have an active ocular infection (bacterial, viral or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (e.g. moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye. Mild dry eye controlled with artificial tears and mild blepharitis controlled with lid scrubs is allowed;

3. have had surgical intervention (ocular or systemic) within 6 months prior to Visit 1, or planned surgical intervention within 30 days thereafter;

4. have had refractive surgery in the past;

5. have dry eye history defined as either current use of Restasis®, past history of insertion of punctual plugs, or daily use of artificial tears more than one drop per day;

6. have a known history of retinal detachment, diabetic retinopathy, or progressive retinal disease;

7. have an intraocular pressure that is less than 5 mmHg or greater than 22 mmHg, or be on any type of intraocular hypertension or any type of glaucoma topical treatment at Visit 1;

8. have red-green color blindness confirmed by Ishihara test during baseline procedures;

9. have an inability or refuse to discontinue contact lens wear 7 days prior to the study visit and during the study visit;

10. have used an investigational drug or device within 30 days of starting the study or be concurrently enrolled in another investigational drug or device study;

11. be a female of childbearing potential who is currently pregnant, nursing or planning a pregnancy; tests positive to a urine pregnancy test at Visit 1; or refuses to use an adequate method of contraception for the duration of the study;

12. have a condition or a situation, which in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation, including but not limited to unstable: cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease;

13. use any of the following disallowed medications during the 2 weeks (14 days) prior to Visit 1 and during the study:

• narcotic (opiate class) pain medication (e.g. codeine, oxycontin, Vicodin®, Tramadol®)

• bladder medication (e.g. urecholine, bethanechol®)

• antipsychotics

• antidepressants

• anticholinergics (e.g. atropine, belladonna, benztropine, dicyclomine, donepezil, hyoscyamine, propantheline, scopolamine, trihexphenidyl

• dry mouth (e.g. salagen®), Evoxac®)

• antihistamines or decongestants

• artificial tear use of more than 1 drop per day

• diagnostic medications required by the protocol are allowed;

14. report of recreational drug use (e.g. marijuana, methadone, heroin, cocaine).

Related Conditions & MeSH terms

• Presbyopia

Intervention

Drug:
• PRX-100
ophthalmic solution
• Placebo
saline ophthalmic solution

Locations

Country	Name	City	State
United States	Andover Eye Associates	Andover	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Presbyopia Therapies, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	binocular assessment of uncorrected near visual acuity		day 1
Secondary	pupil diameter		day 1